WO2017159725A1 - Composition pour favoriser la sécrétion de glp-1, et son procédé de fabrication - Google Patents

Composition pour favoriser la sécrétion de glp-1, et son procédé de fabrication Download PDF

Info

Publication number
WO2017159725A1
WO2017159725A1 PCT/JP2017/010362 JP2017010362W WO2017159725A1 WO 2017159725 A1 WO2017159725 A1 WO 2017159725A1 JP 2017010362 W JP2017010362 W JP 2017010362W WO 2017159725 A1 WO2017159725 A1 WO 2017159725A1
Authority
WO
WIPO (PCT)
Prior art keywords
component
function
composition
bitter gourd
glp
Prior art date
Application number
PCT/JP2017/010362
Other languages
English (en)
Japanese (ja)
Inventor
斉志 渡辺
寿栄 鈴木
阿部　圭一
学 堀川
鋭明 東
Original Assignee
サントリーホールディングス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントリーホールディングス株式会社 filed Critical サントリーホールディングス株式会社
Priority to JP2018505974A priority Critical patent/JP6802256B2/ja
Publication of WO2017159725A1 publication Critical patent/WO2017159725A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/42—Cucurbitaceae (Cucumber family)

Definitions

  • the present invention relates to a composition useful for activation (or promotion) of GLP-1 (or GLP-1 secretion), and a method for producing the same.
  • the present invention also relates to a novel compound useful for activation of GLP-1 secretion (or promotion of GLP-1 secretion) and the like.
  • GLP-1 [Glucagon-like peptide-1] is a gastrointestinal hormone secreted from the gastrointestinal mucosal epithelium. Such actions of GLP-1 are known to stimulate insulin synthesis and secretion, inhibit glucagon secretion, inhibit food intake, reduce hyperglycemia, and the like. Therefore, activation of GLP-1 can be expected to improve these effects.
  • bitter gourd (nigauri) is a plant that is edible and cultivated, and studies on the physiological effects of bitter gourd are also being made.
  • Non-Patent Document 1 a specific compound contained in bitter gourd has an activation action of GLP-1, and has a blood glucose regulating function. It is reported that it may have.
  • An object of the present invention is to provide a composition useful for promoting or activating GLP-1 secretion (GLP-1 response). Another object of the present invention is to suppress an increase in blood glucose level, to suppress appetite, to suppress overeating, to improve glucose metabolism, to prevent or treat diabetes, to prevent or treat obesity, to reduce body weight, to body fat An object of the present invention is to provide a composition useful for reducing the rate. Still another object of the present invention is to provide a method for efficiently producing a compound useful for activation of GLP-1 secretion or the like or a composition containing this compound. Another object of the present invention is to provide a novel compound useful for promoting or activating GLP-1 secretion.
  • the composition of the present invention includes at least one component (A) selected from the following formulas (1) to (11) (included as an active component). Since such a composition has an activation effect on GLP-1 secretion, it can be used as a composition for promoting GLP-1 secretion (a composition for activating GLP-1).
  • the composition of the present invention has a GLP-1 secretion promoting action, it may be suitably used for applications intended for actions / functions resulting from or related to the action.
  • the composition of the present invention is used for suppressing blood glucose level elevation, appetite suppression, overeating, glucose metabolism improvement, diabetes prevention or treatment, obesity prevention or treatment, weight reduction, and It may be a composition for use in at least one application selected from those for reducing body fat percentage.
  • the composition of the present invention is used for suppressing an increase in blood glucose level, for suppressing appetite, for suppressing overeating, for improving glucose metabolism, for preventing or treating diabetes, for preventing or treating obesity, for reducing body weight, and It may be a composition for use in at least one application selected from those for reducing body fat percentage.
  • At least one function (or action) selected from (function), weight reduction (function), and body fat percentage reduction (function) may not necessarily result from GLP-1 secretion promotion. -1 secretion promotion may be caused.
  • the component (A) may particularly contain at least one component (A1) selected from the above formulas (6) to (11).
  • the composition of the present invention may contain the component (A) as a component derived from bitter gourd (particularly, a component derived from heat-treated bitter gourd).
  • the form of the composition of the present invention may be, for example, solid (for example, powder) or liquid.
  • the present invention includes a liquid composition containing at least one component (A) selected from the above formulas (1) to (11).
  • a liquid composition may contain the component (A) at a ratio of 0.005 ppm or more on a mass basis.
  • the component (A) may particularly include at least one component (A1) selected from the formulas (6) to (11).
  • the components (A) to ( At least one component (A1) selected from 11) may be contained in a proportion of 0.005 ppm or more based on mass.
  • composition (or liquid composition) of the present invention may be, for example, a puree or a beverage, in particular, a heat-treated bitter gourd puree or a beverage.
  • composition of the present invention may be used for addition to food or drink (or as an additive for food or drink).
  • the present invention includes foods and drinks containing the composition.
  • a food or drink may contain, for example, at least one component (A) selected from the formulas (1) to (11) in a proportion of 0.005 ppm or more based on mass.
  • food / beverage products may contain the non-bitter gourd origin component normally.
  • the food and drink may be a beverage.
  • the composition or food or drink of the present invention has a GLP-1 secretion promoting action, and also has a function attributable to or related to the action. Therefore, the composition or food / beverage product of the present invention may be a composition or food / beverage product with an indication of the function of promoting GLP-1 secretion and / or the function resulting from the promotion of GLP-1 secretion.
  • a composition or food and drink include, for example, a blood glucose level increase suppressing function, an appetite suppressing function, an overeating suppression function, a glucose metabolism improving function, a diabetes prevention or treatment function, an obesity prevention or treatment function,
  • subjected the display (functional display) of the at least 1 function selected from the reduction function and the reduction function of a body fat ratio (a function which can be equated with these) are contained.
  • the component (A) can be efficiently generated by heat-treating the bitter gourd component. Therefore, the present invention provides a method for expressing or increasing at least one component (A) selected from the above formulas (1) to (11) in the bitter gourd component, the heating step for heat treating the bitter gourd component Including methods.
  • the present invention also includes a method for producing the composition, which includes a heating step of heat-treating bitter gourd ingredients.
  • puree or beverage (especially puree) of bitter gourd ingredients may be heat-treated in the heating step.
  • the compound selected from the formulas (6) to (11) is a novel compound. Therefore, the present invention also includes compounds selected from the formulas (6) to (11).
  • the composition and food or drink of the present invention usually have a GLP-1 secretion promoting action (or GLP-1 activation action). Therefore, the present invention also includes a method of activating GLP-1 (or promoting secretion of GLP-1) by ingesting, taking or administering the composition or food or drink. Since such a method can activate the secretion of GLP-1, it can be applied to symptoms caused by or related to the activation effect of GLP-1 secretion. For example, such a method is selected from suppression of an increase in blood glucose level, suppression of appetite, suppression of overeating, improvement of glucose metabolism, prevention or treatment of diabetes, prevention or treatment of obesity, weight reduction, and reduction of body fat percentage. Alternatively, at least one method may be used.
  • the composition or food or drink is ingested, taken or administered, suppression of blood sugar level increase, suppression of appetite, suppression of overeating, improvement of glucose metabolism, prevention or treatment of diabetes, prevention or treatment of obesity
  • methods of performing (or realizing) at least one selected from weight reduction and body fat percentage reduction In such a method, it is not always necessary to involve activation of GLP-1 (secretion promotion), and it may be accompanied by activation of GLP-1 (secretion promotion).
  • the subject of ingestion, administration or administration may be an animal, and may be a human or a non-human animal (dog, cat, etc.).
  • a composition useful for activation (or promotion) of GLP-1 (or GLP-1 secretion) can be provided. Since such a composition has a GLP-1 activation action, the action / function resulting from or related to the action, for example, a blood glucose level increase suppressing action, an appetite suppressing action, an overeating inhibitory action, an action of improving sugar metabolism, It can be suitably used as a composition for the purpose of preventing or treating diabetes, preventing or treating obesity, reducing body weight, reducing body fat percentage, and the like.
  • the composition of the present invention can also be used for obesity prevention / treatment, diet, diabetes prevention / treatment, and the like.
  • the timing of ingestion (taking) of the composition of the present invention is not particularly limited, and can be used, for example, for before meals (for intake before meals), between meals, for after meals, and the like.
  • the composition of the present invention can be suitably used for diseases that require improvement of glucose metabolism since it can promote secretion of GLP-1 to improve glucose metabolism.
  • diseases can include diabetes and obesity and are effective in their prevention and treatment. Therefore, the composition of the present invention can be provided with an indication that the composition is used for the prevention and / or improvement of hyperglycemia and obesity, for example, and the subject has a high blood sugar level. It is extremely useful for a person who has a tendency to gain weight, a person who is overweight, a person who has a tendency to have metabolic syndrome, and the like.
  • composition (or compound) of the present invention is stable against heat and long-term storage, and can also exist stably in vivo (for example, under exposure to gastric acid). Therefore, it can be suitably used as an additive for food and drink.
  • composition as described above or a compound contained in the composition and useful for activation of GLP-1 can be efficiently produced.
  • the present invention can provide a novel compound useful for the activation of GLP-1.
  • FIG. 1 is a graph showing the amount of GLP-1 secretion of each component in Example 3, assuming that the control is 100 in Example 3.
  • FIG. 2 is a chromatogram of LC-MS analysis of the acetone extract and fraction 2 obtained in Example 3.
  • FIG. 3 is a graph showing the change over time (100 ° C.) in the amount of each component in Example 6.
  • FIG. 4 is a graph showing the change with time (120 ° C.) of the amount of each component in Example 6.
  • FIG. 5 is a graph showing the results of the stability test of each component in Example 7.
  • FIG. 6 is a graph showing the blood glucose level measurement results in Example 9.
  • composition of the present invention comprises a component (A) selected from the following formulas (1) to (11).
  • the component (A) may contain at least one compound among the compounds (1) to (11), and may contain a combination of two or more compounds.
  • the compounds (6) to (11) are novel compounds, and such novel compounds are also included in the present invention.
  • the names (common names) of these novel compounds are as shown in the following table.
  • the names of the compounds (1) to (5) are as follows.
  • Compound 1 momordicoside I
  • Compound 2 5 ⁇ , 19-epoxycucurbita-6,23 (E) -diene-3 ⁇ , 19,25-triol (5 ⁇ , 19-epoxycucurbita-6,23 (E) -diene-3,19,25-triol )
  • Compound 3 7,23-dihydroxy-3-O-malonylcucurbita-5,24-dien-19-al (7,23-dihydroxy-3-O-malonylcucurbita-5,24-dien-19-al)
  • Compound 4 momordicoside W
  • Compound 5 momordicoside P
  • composition of the present invention may contain at least one component (A1) selected from compounds (6) to (11).
  • composition of the present invention may contain component (A) (or compounds (1) to (11)) in the form of a derivative as long as it has an action of activating GLP-1 secretion.
  • component (A) or compounds (1) to (11)
  • such derivatives include salts, solvates (such as hydrates), ethers [for example, in compounds (1) to (11), a part or all of the hydroxyl groups are alkoxy groups (for example, methoxy groups).
  • such a derivative may be derived from, for example, an extraction solvent used for separating or separating the component (A) from bitter gourd or the like.
  • Component (A) (or compounds (1) to (11) and derivatives thereof) may be synthesized by a conventional method, but efficiently from plants, especially bitter gourd (heat-treated bitter gourd) as described later. Obtainable.
  • the composition of the present invention may contain the component (A) as a bitter gourd-derived component (bitter gourd component), particularly as a heat-treated bitter gourd-derived component (bitter gourd component).
  • bitter gourd ingredients may usually be processed bitter gourd.
  • processed bitter gourd products include purees, beverages, pulverized products, extracts, and dried products (dried products).
  • the beverage may be juice.
  • the bitter gourd component may be a mixture thereof.
  • composition of the present invention is not particularly limited as long as it contains the component (A), and may be solid (such as powder) or liquid.
  • composition of the present invention may be liquid.
  • puree, a drink, etc. are mentioned, for example.
  • the component (A) is easily obtained as a bitter gourd-derived component, and even if the bitter gourd component (the bitter gourd-derived component) other than the component (A) is contained, the GLP-1 activity may be impaired. Absent.
  • the composition of the present invention may in particular be bitter gourd (especially heat-treated bitter gourd) powder (for example, dried product), puree, beverage (particularly puree) and the like.
  • bitter gourd especially heat-treated bitter gourd
  • puree for example, dried product
  • beverage particularly puree
  • you may concentrate or dilute a puree or a drink as needed.
  • composition of the present invention may be composed of only component (A) as long as it has GLP-1 activating action, and may contain other components (such as bitter gourd-derived components other than component (A)). .
  • the ratio of the component (A) can be selected from a range of about 0.005 ppm or more (for example, 0.01 to 10,000 ppm), for example, on a mass basis. It may be about 5 ppm or more (for example, 0.6 to 6000 ppm), more preferably about 1 ppm or more (for example, 5 to 1000 ppm), or about 10 ppm or more (for example, 20 to 800 ppm, preferably about 50 to 500 ppm). Also good.
  • the ratio of the component (A1) can be selected from a range of, for example, about 0.005 ppm or more (eg, 0.01 to 10000 ppm) on a mass basis, It may be about 5 ppm or more (for example, 0.6 to 6000 ppm), more preferably about 1 ppm or more (for example, 5 to 1000 ppm), or about 10 ppm or more (for example, 20 to 800 ppm, preferably about 50 to 500 ppm). May be.
  • composition of the present invention has a GLP-1 activation action (or GLP-1 secretion promoting action) and the like. Therefore, the composition of the present invention can be used for GLP-1 activation or the like (or as a composition having a GLP-1 activation effect).
  • the composition of the present invention has a GLP-1 activating action, and is related to the action, for example, a blood sugar level increase suppressing action, an appetite suppressing action, an overeating suppressing action, a glucose metabolism improving action, a diabetes It can be suitably used as a composition for the purpose of preventing or treating the above, for preventing or treating obesity, for reducing the body weight, for reducing the body fat percentage, and the like.
  • the usage method (application method) of the composition of the present invention can be appropriately selected according to the form of the composition.
  • the composition of the present invention may be used as it is (taken, taken, administered, etc.), and the composition of the present invention is formulated with other components (carrier, excipient, etc.) and used (taken). , Taking, administering, etc.).
  • Examples of other components include excipients, binders, disintegrants, coating agents, lubricants, coloring agents, flavoring agents, stabilizers, emulsifiers, absorption accelerators, surfactants, pH adjusters. Formulations, preservatives, antioxidants and the like.
  • the formulation method is not particularly limited, and a conventional method can be applied.
  • examples of the dosage form include tablets, powders, fine granules, granules, dry syrups, coated tablets, orally disintegrating tablets, chewable tablets, capsules, soft capsules, and syrups.
  • composition of the present invention may be used (ingested, taken, administered, etc.) added to (or included in) a food or drink.
  • the food and drink includes not only general foods including so-called health foods but also health foods such as foods for specified health use and functional foods for nutrition.
  • the food and drink also includes supplements (dietary supplements), feeds and the like.
  • Food / beverage products may contain other components such as food additives (food additives) as long as they contain the composition of the present invention.
  • the food additive is not particularly limited. Calcium silicate, etc.), binder (eg, pregelatinized starch, hydroxypropylmethylcellulose, polyvinylpyrrolidone, etc.), disintegrant (eg, cellulose, hydroxypropylcellulose, corn starch, etc.), fluidizing agent (eg, light anhydrous silicic acid) Sucrose fatty acid esters, etc.), oils (eg, vegetable oils such as soybean oil, sesame oil, olive oil, linseed oil, sesame oil, rapeseed oil, coconut oil, corn oil, etc.), nutrients (eg, various Minera , Various vitamins, amino acids), flavorings, sweeteners, flavoring agents, coloring agents, solvents (ethanol), salts, surfactants, pH regulators, buffers, antioxidants, stabilizers, gelling agents, thickening Agents, lubricants
  • the other component may be a non-bitter gourd derived component.
  • the food or drink is not particularly limited.
  • food e.g., noodles (soba, udon, Chinese noodles, instant noodles, etc.) ), Tofu, confectionery (rice cakes, candy, gum, chocolate, snacks, biscuits, cookies, gummi, etc.), breads, fishery or livestock processed foods (kamaboko, ham, sausage, etc.), dairy products (processed milk, fermented milk) Etc.), fats and oils and processed foods (salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing, etc.), seasonings (sauce, sauce, etc.), cooked or semi-cooked products (chample, etc.), retort food ( Curry, stew, rice cake, porridge, miscellaneous cooking, etc.), frozen dessert (ice cream, sorbet, shaved ice, etc.)], beverage ( Beverages, soft drinks, carbon
  • the food and drink may be a beverage (especially a bitter gourd beverage).
  • the ratio of the composition (or component (A)) of the present invention can be selected from a range of, for example, about 0.005 ppm or more (for example, 0.01 to 10,000 ppm) based on the mass of the component (A).
  • 0.5 ppm or more for example, 0.6 to 6000 ppm
  • more preferably about 1 ppm or more for example, 5 to 1000 ppm
  • about 10 ppm or more for example, 20 to 800 ppm, preferably about 50 to 500 ppm. It may be.
  • the ratio of the composition (or component (A)) of the present invention is, for example, in the range of about 0.005 ppm or more (for example, 0.01 to 10000 ppm) based on the mass of the component (A1). 0.5 ppm or more (for example, 0.6 to 6000 ppm), more preferably about 1 ppm or more (for example, 5 to 1000 ppm), or 10 ppm or more (for example, 20 to 800 ppm, preferably 50 to 500 ppm). ) Degree.
  • intake is not specifically limited, although it can select suitably according to object age, weight, health condition, etc., for example, 1 day
  • Per unit amount in terms of component (A) is 0.001 mg or more (eg, 0.001 to 10000 mg), preferably 0.01 mg or more (eg, 0.05 to 5000 mg), more preferably 0.1 mg or more.
  • 0.5 to 1000 mg particularly about 1 mg or more (for example, 5 to 500 mg) may be used.
  • composition and food and drink of the present invention can be used or applied for either therapeutic use (medical use) or non-therapeutic use. Specifically, regardless of whether it is classified as a pharmaceutical, a quasi-drug, or a cosmetic, the function that promotes the secretion of GLP-1 and the function that results from the promotion of GLP-1 secretion are explicitly or It can be used or applied as any implicitly appealing composition or food or drink. In addition, the composition and the food and drink of the present invention may display a function that promotes secretion of GLP-1 and a function caused by promotion of secretion of GLP-1.
  • Such a display is not particularly limited, but is a GLP-1 secretion promoting function or a function resulting from the promotion of GLP-1 secretion, such as a blood glucose level increase inhibiting function, an appetite suppressing function, an overeating suppressing function, a glucose metabolism Improvement function, diabetes prevention or treatment function, obesity prevention or treatment function, weight reduction function, body fat percentage reduction function, or display that can be equated with these.
  • a display may be attached
  • composition (or component (A)) of the present invention may be produced by a synthetic method, it can be produced particularly efficiently using a bitter gourd component.
  • the present invention includes a method for producing the composition (or component (A)) through at least a heating step of heat-treating the bitter gourd component.
  • the present invention also includes a method of expressing or increasing the component (A) in the bitter gourd component through at least the heating step.
  • the bitter melon component is not particularly limited as long as it contains the component that generates the component (A), such as bitter gourd (bitter melon body), fruit (or pulp), skin, cotton, seed, seed coat, etc. Or a mixture thereof.
  • bitter gourd often uses at least a fruit-containing portion (eg bitter gourd, pulp).
  • the bitter gourd component may be processed bitter gourd.
  • the bitter gourd component may be heat-treated as it is, but for example, it is preferably heat-treated as puree, such as puree or beverage, particularly as puree. By heat-treating such bitter gourd puree or the like, the component (A) can be efficiently generated or expressed. Puree and the like may be concentrated or diluted as necessary. Further, the bitter gourd component may be subjected to heat treatment (or heat treatment of the bitter gourd component containing the acid component) in the presence of an acid component (for example, an organic acid such as acetic acid or citric acid). By heat-treating in the presence of an acid component, the component (A) can be easily generated efficiently.
  • an acid component for example, an organic acid such as acetic acid or citric acid
  • the heating temperature can be appropriately selected depending on the heating time and the like, but is, for example, 40 ° C. or higher (eg, 40 to 160 ° C.), preferably 60 ° C. or higher (eg, 60 to 140 ° C.), and more preferably. May be about 80 ° C. or higher (for example, 80 to 120 ° C.).
  • the heating time is, for example, about 1 minute or more (for example, 1 to 60 minutes), preferably about 5 minutes or more (for example, 5 to 40 minutes), more preferably about 10 minutes or more (for example, 10 to 30 minutes). It may be.
  • the heating method can be appropriately selected according to the form of bitter gourd component and the like, and is not particularly limited, and may be any of resistance heating, induction heating, dielectric heating (such as microwave heating) and the like. Moreover, a heating means can be suitably selected according to a heating method. Depending on the form of the bitter gourd ingredient, it may be heated by boiling, cooking, baking, steaming, or hot water.
  • Heating may be performed in an active atmosphere (such as an air atmosphere) or in an inert atmosphere. Moreover, you may heat by a closed system. In particular, the component (A) can be efficiently generated by heating in a closed system.
  • the bitter gourd component (heated bitter gourd component) after the heating step may be used as it is or may be purified according to the form of the composition.
  • the bitter gourd component after the heat treatment may be concentrated or diluted as it is.
  • a composition containing the component (A) in a high proportion from the bitter gourd component after the heat treatment may be obtained using a conventional technique such as extraction. .
  • Example 1 Separation and identification of compounds (1) to (11) (extraction and crude fractionation)
  • Bitter gourd chips (20 kg) were extracted with methanol (MeOH) to obtain a MeOH extract.
  • the obtained MeOH extract was partitioned with 50% aqueous MeOH-hexane (1: 1, 60 L).
  • the soluble part of 50% MeOH aqueous solution was adsorbed on an ion exchange resin [Made by Mitsubishi Chemical, Diaion HP-20 (resin amount: 30 L)] and eluted with 50% MeOH aqueous solution (100 L) and MeOH (100 L).
  • the solvent was distilled off to obtain 50% MeOH fraction and MeOH fraction (114 g).
  • tip is a heating air dried product, it is heat-processed.
  • MeOH fraction (5.0 g) was separated into 19 fractions by medium pressure preparative liquid chromatograph (MPLC) (ODS, water-MeOH) and MPLC (ODS, 20 mM CH 3 COONH 4 aqueous solution-CH 3 CN, acetone). I drew it.
  • Fraction 7 was purified by high performance liquid chromatography (HPLC) (manufactured by YMC, Triart C18, water-CH 3 CN) to obtain compound (3) (25.0 mg). Further, the fraction 9 was purified by HPLC (manufactured by YMC, Triart C18, water-CH 3 CN) to isolate the compound (7) (18.3 mg).
  • HPLC high performance liquid chromatography
  • Fractions 12 and 16 were similarly purified by HPLC (manufactured by YMC, Triart C18, water-CH 3 CN), and from fraction 12, compound (11) (0.8 mg) was purified from fraction 16 to compound ( 6) (1.0 mg) was obtained.
  • Fractions 9 and 10 were similarly purified by HPLC (manufactured by YMC, Trial C18, H 2 O—CH 3 CN). Fraction 9 to compound (5) (17.1 mg) were purified from fraction 10 to compound ( 1) (43.5 mg) was obtained. Fractions 16 and 17 were combined, MPLC (ODS, 20 mM CH 3 COONH 4 aqueous solution—CH 3 CN, acetone), HPLC (YMC, Triart C18, water—CH 3 CN) and HPLC (Nacalai Tesque, Purification with Cosmosil PBr, water-CH 3 CN) gave Compound (2) (10.7 mg), Compound (10) (3.8 mg), and Compound (8) (4.6 mg).
  • the structures of the compounds (1) to (11) were identified by mass spectrometry and NMR, and confirmed to be the structures as described above. An example of structural analysis data is shown below.
  • Example 2 Confirmation of GLP-1 Secretion Promoting Action
  • 150 ml of water was added to dried bitter gourd chips (10.5 g) and heated to reflux for 1 hour.
  • the reaction product was extracted by adding 150 ml of acetone and then filtered. The residue was re-extracted with 100 ml of acetone. After filtration, the filtrates were combined and concentrated under reduced pressure to obtain 3.46 g of an acetone extract. It was confirmed that the compounds (1) to (11) obtained in Example 1 and the acetone extract obtained as described above have GLP-1 secretion activity.
  • the results of comparing the compounds (1) to (5) and (7) with the control are shown in the following table.
  • the table also shows the results of TPA (3 ⁇ M), which is known to have a GLP-1 secretion activation effect.
  • the GLP-1 secretion activation action was confirmed as follows.
  • Poly-L-Lysine 96-well plates are BD, PBS (+), antibiotics, Dulbecco's Modified Eagle's Medium (DMEM), glucose, carboxymethylcellulose Sodium salt (CMC-Na) is manufactured by Nacalai Tesque, TPA [12-O-tetradecanoylphorbol-13-acetate] is manufactured by Cell Signaling, and active GLP-1 ELISA kit is Merck Millipore, Fetal bovine serum (FBS) manufactured by Sigma, Sitagliptin phosphate (Santagliptin phosphate) a Cruz Biotechnology, NCI-H716 cells assigned from ATCC were used.
  • NCI-H716 cells suspended in DMEM medium (10% FBS, 2 mM glutamine, 1% antibiotics added) are seeded on a Poly-L-Lycine 96-well plate at 100 ⁇ L at 0.5 ⁇ 105 cells / well.
  • the cells were cultured in a CO2 incubator (manufactured by espec) for 48 hours.
  • Example 3 Method for preparing fraction containing a large amount of GLP-1 secretion promoting active ingredient 150 ml of water was added to dried bitter gourd chips (10.5 g), and the mixture was heated to reflux for 1 hour. The reaction product was extracted by adding 150 ml of acetone and then filtered. The residue was re-extracted with 100 ml of acetone. After filtration, the filtrates were combined and concentrated under reduced pressure to obtain 3.46 g of an acetone extract. The obtained acetone extract was fractionated by MPLC (ODS), and a water-eluted fraction (fraction 1: 3.1 g), an acetonitrile-eluted fraction (fraction 2: 210 mg), and an acetone-eluted fraction (fraction 3). : 140 mg). Each fraction and acetone extract were confirmed to have GLP-1 secretion activity in the same manner as in Example 2.
  • TPA 3 ⁇ M
  • Fr means “fraction”
  • bitter gourd means an acetone extract.
  • fraction 2 contained compounds (1) to (11).
  • Example 4 Quantification of compounds (1) to (5) In each sample shown below, compounds (1) to (5) were picked up from compounds (1) to (11) and analyzed by LC-MS. Was quantified.
  • the analysis conditions were as follows. (LCMS measurement) Each sample was analyzed by LCMS-IT-TOF and quantified. The quantitative value was obtained from a calibration curve prepared in advance using a standard. (LC conditions) Column: Triart C18 (YMC, 150 ⁇ 2.1 mm ID, 3 ⁇ m) Column temperature: 40 ° C Flow rate: 0.3 ml / min Gradient: 30% ⁇ 100% (30-39 minutes) B in A A: 0.1% formic acid aqueous solution B: 0.1% formic acid acetonitrile injection amount: 2 ⁇ l
  • Example 5 Comparison of content of compounds (1) to (5) depending on heating temperature Lying dried powder (50 mg) of bitter gourd was weighed into a test tube with a lid, and 3 ml of water was added and sealed. Using a microwave synthesizer (CEM Discover), it was heated at 100, 120, 140 or 160 ° C. for 10 minutes. After heating, 7 ml of acetonitrile was added to the reaction product and extracted with ultrasound for 2 minutes. After standing, the supernatant was filtered with a 0.45 ⁇ m filter to obtain an analysis sample. In each of the obtained samples, compounds (1) to (5) were quantified by LC-MS analysis in the same manner as in Example 4.
  • CEM Discover microwave synthesizer
  • Example 6 Time-dependent change in content of compounds (1) to (5) under heat treatment conditions A bitter gourd freeze-dried powder (50 mg) was weighed in a tester with a lid and sealed with 3 ml of water. Heating was performed at 100 ° C. and 120 ° C. for 2, 5, 10, 20, 40 or 60 minutes using a microwave synthesizer (CEM Discover). After heating, 7 ml of acetonitrile was added to the reaction product and extracted with ultrasound for 2 minutes. After standing, the supernatant was filtered with a 0.45 ⁇ m filter to obtain an analysis sample. In each of the obtained samples, compounds (1) to (5) were quantified by LC-MS analysis in the same manner as in Example 4.
  • CEM Discover microwave synthesizer
  • Example 7 Stability test of compounds (1) to (5) 0.5 mL of 70% acetonitrile mixed solution and 0.2N hydrochloric acid aqueous solution containing compounds (1) to (5) at a concentration of 4 ⁇ g / mL, respectively. A 5 mL mixed solution was prepared, and the amount of the compounds (1) to (5) when allowed to stand at 40 ° C. was measured over time. The measurement was performed by LC-MS analysis in the same manner as in Example 4.
  • Example 8 Confirmation of GLP-1 activating action by heated puree Using the bitter gourd puree (heated puree) obtained in Example 4, the in vivo GLP-1 activating action was confirmed under the following conditions.
  • the heated puree group was found to have an action of activating GLP-1 secretion in vivo.
  • Example 9 Confirmation of blood glucose level increase inhibitory effect by heating puree Using the heated puree obtained in Example 4, the in vivo GLP-1 activation effect was confirmed under the following conditions.
  • Oral glucose tolerance test The blood glucose level of the mice fasted for about 5 hours was measured, and the control group, the low-dose group, and the high-dose group were distributed to the control group, the low-dose group, and the high-dose group by the stratified extraction method using the blood glucose level.
  • the administered substance was orally administered to each group, and 0.5 g of glucose (20% solution, 10 mL / kg) was orally administered 0.5 hours later.
  • Blood glucose levels were collected from the tail vein under non-anesthesia before administration of the administered substance (-0.5 hours), immediately before glucose administration (0 hours), and at 0.5, 1, 2, and 3 hours after glucose administration. The measurement was performed using a measuring device (Glutest Neo Super, Sanwa Chemical Laboratory Co., Ltd.).
  • the blood glucose level of the control group showed an increase that peaked at 0.5 hours after glucose administration, and then decreased.
  • Both the low-dose group and the high-dose group of heat puree administration showed the same transition as the control group, but the low-dose group showed a tendency to suppress the increase in blood glucose level, and the high-dose group showed a significant low blood glucose level. The tendency was observed up to 1 hour after glucose administration.
  • Example 10 Manufacture of tea beverage 20 g of bitter gourd pure obtained in Example 4 is added to 200 ml of tea extract (prepared to 0.3% by mass by adding water to commercially available powdered green tea), and sencha beverage Manufactured.
  • Example 11 Manufacture of coffee beverage Coffee extract was prepared in a conventional manner using 65 g of boiling water to 5 g of ground commercial coffee powder, and 5 g of bitter gourd pure obtained in Example 4 was added. A beverage was produced.
  • Example 12 Manufacture of vegetable beverages Add 1 banana, 1 carrot, 1 bunch of salad vegetables, 30g of bitter gourd puree obtained in Example 4, 200ml of water and 3 tablespoons of sugar to a food processor. Obtained.
  • Example 13 Manufacture of biscuits Using conventional methods, 85 g of wheat flour, 30 g of sugar, 1 g of baking powder, 1 g of salt, 25 g of sesame oil, 20 g of milk, and 1 g of bitter gourd puree obtained by freeze-drying the bitter gourd pure obtained in Example 4 Biscuits were manufactured.
  • Example 14 Production of tofu 600 ml of well-cooled soymilk (no adjustment), 15 ml of bittern, 30 ml of water, 5 g of bitter gourd puree obtained in Example 4 were poured into a heat-resistant tapper and mixed. Wrapped and steamed for about 15 minutes on low heat with a steamed steamer to produce tofu.
  • a composition useful for activation of GLP-1 secretion can be provided.
  • such a composition can be produced efficiently.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Tea And Coffee (AREA)
  • Bakery Products And Manufacturing Methods Therefor (AREA)

Abstract

La présente invention concerne une composition utilisable pour activer la sécrétion de GLP-1. Ladite composition peut être conçue à partir d'un composé spécifique tel que le composé (1). Le composé spécifique de l'invention peut être obtenu avec une bonne efficacité par traitement thermique d'un composant de Momordica charantia (par exemple une purée de Momordica charantia ou similaire), par exemple.
PCT/JP2017/010362 2016-03-16 2017-03-15 Composition pour favoriser la sécrétion de glp-1, et son procédé de fabrication WO2017159725A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018505974A JP6802256B2 (ja) 2016-03-16 2017-03-15 Ｇｌｐ−１分泌促進用組成物及びその製造方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016053163 2016-03-16
JP2016-053163 2016-03-16

Publications (1)

Publication Number Publication Date
WO2017159725A1 true WO2017159725A1 (fr) 2017-09-21

Family

ID=59851258

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/010362 WO2017159725A1 (fr) 2016-03-16 2017-03-15 Composition pour favoriser la sécrétion de glp-1, et son procédé de fabrication

Country Status (3)

Country Link
JP (1) JP6802256B2 (fr)
TW (1) TW201808305A (fr)
WO (1) WO2017159725A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020125243A (ja) * 2019-02-01 2020-08-20 国立研究開発法人水産研究・教育機構 セレノネインモノマーの分離方法
WO2020218380A1 (fr) 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Composition favorisant la sécrétion de glp-1
WO2020218379A1 (fr) 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Composition favorisant la sécrétion de glp-1
WO2020218382A1 (fr) * 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Sécrétagogue de glp-1
WO2022215619A1 (fr) 2021-04-07 2022-10-13 株式会社林原 Composition favorisant la sécrétion de glp-1

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109833337B (zh) * 2019-01-18 2021-08-03 华南农业大学 一种抑制害虫免疫反应的苦瓜素类化合物及其高效制备方法和应用
CN114874314B (zh) * 2021-12-28 2022-11-11 北京惠之衡生物科技有限公司 一种高表达glp-1类似物的重组工程菌及其构建方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020925A (ja) * 2009-07-13 2011-02-03 Ikeda Shokken Kk 内臓脂肪型肥満抑制剤及びその製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011020925A (ja) * 2009-07-13 2011-02-03 Ikeda Shokken Kk 内臓脂肪型肥満抑制剤及びその製造方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DANIEL BISRAT MEKURIA ET AL.: "Cucurbitane triterpenoid oviposition deterrent from Momordica charantia to the leafminer, Liriomyza trifolii", BIOSCIENCE, BIOTECHNOLOGY, AND BIOCHEMISTRY, vol. 69, no. 9, 2005, pages 1706 - 10, XP055422878 *
LIVA HARINANTENAINA ET AL.: "Momordica charantia constituents and antidiabetic screening of the isolated major compounds", CHEM PHARM BULL, vol. 54, no. 7, 2006, pages 1017 - 21, XP008139769 *
LU WEI ET AL.: "Increase in the free radical scavenging capability of bitter gourd by a heat-drying process", FOOD & FUNCTION, vol. 4, no. 12, 2013, pages 1850 - 5, XP055422868 *
MASAKI WATANABE ET AL.: "Tonyobyo Rat no Shishitsu Taisha ni Oyobosu Nigauri Funmatsu Choseiji ni Okeru Kanso Shoriho no Eikyo", PROCEEDINGS OF JAPANESE SOCIETY OF FOOD SCIENCE AND TECHNOLOGY, vol. 50, no. 67, 2003, pages 3Ga4 *
NGUYEN XUAN NHIEM ET AL.: "Cucurbitane-type triterpene glycosides from the fruits of Momordica charantia", MAGNETIC RESONANCE IN CHEMISTRY, vol. 48, no. 5, 2010, pages 392 - 6, XP055422885 *
PING-CHUN HSIAO ET AL.: "Antiproliferative and hypoglycemic cucurbitane-type glycosides from the fruits of Momordica charantia", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 61, no. 12, 2013, pages 2979 - 86, XP055422871 *
QING YAN LIA ET AL.: "A new cucurbitane triterpenoid from Momordica charantia", CHINESE CHEMICAL LETTERS, vol. 18, no. 7, 2007, pages 843 - 5, XP022139807 *
TING-NI HUANG ET AL.: "Role of GLP-1 in the Hypoglycemic Effects of Wild Bitter Gourd", EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, vol. 2013, no. 625892, 2013, pages 1 - 13, XP055422866 *
ZHEN-JIE LI ET AL.: "Two New Cucurbitane Triterpenoids from Immature Fruits of Momordica charantia", HELVETICA CHIMICA ACTA, vol. 98, no. 10, 2015, pages 1456 - 61 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020125243A (ja) * 2019-02-01 2020-08-20 国立研究開発法人水産研究・教育機構 セレノネインモノマーの分離方法
JP7233085B2 (ja) 2019-02-01 2023-03-06 国立研究開発法人水産研究・教育機構 セレノネインモノマーの分離方法
WO2020218380A1 (fr) 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Composition favorisant la sécrétion de glp-1
WO2020218379A1 (fr) 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Composition favorisant la sécrétion de glp-1
WO2020218382A1 (fr) * 2019-04-26 2020-10-29 サントリーホールディングス株式会社 Sécrétagogue de glp-1
WO2022215619A1 (fr) 2021-04-07 2022-10-13 株式会社林原 Composition favorisant la sécrétion de glp-1

Also Published As

Publication number Publication date
JPWO2017159725A1 (ja) 2019-01-17
TW201808305A (zh) 2018-03-16
JP6802256B2 (ja) 2020-12-16

Similar Documents

Publication Publication Date Title
JP6802256B2 (ja) Ｇｌｐ−１分泌促進用組成物及びその製造方法
CA2854281C (fr) Agent de prevention de l'atrophie musculaire
JP6541582B2 (ja) ユズ種子抽出物含有組成物、骨格筋増量用食品、およびユズ種子抽出物含有組成物の製造方法
AU2003221344B2 (en) Process for producing SDG and foods and drinks containing the same
JP6112895B2 (ja) メタボリックシンドロームの予防、改善または治療用組成物
JP6294710B2 (ja) 糖代謝改善剤
KR102189891B1 (ko) 쌀겨 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물
KR20220000892A (ko) 새싹보리 추출물을 포함하는 남성 갱년기 증후군 예방 또는 치료용 조성물
JP5175442B2 (ja) ヤーコン由来の抗ガン剤
JP6273440B2 (ja) Ｇｌｐ−１産生促進剤、ｄｐｐｉｖ阻害剤及びグルコース吸収阻害剤
AU2013367872B2 (en) Igf-1 production-promoting agent
JP2009073761A (ja) レプチン産生促進剤
JP6044944B2 (ja) 新規梅加工品の製造方法及びこれを用いた機能性組成物、食品組成物、医薬組成物
JP2002363086A (ja) 骨代謝改善剤及び骨粗鬆症の予防又は治療用飲食物
JP6462755B2 (ja) 脳の機能改善剤および脳の機能改善用飲食品
KR101406126B1 (ko) 백운풀 추출물을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물
JP7156639B2 (ja) レスベラトロール誘導体の新規用途
JP2019205386A (ja) α−グルコシダーゼ活性阻害剤および血糖値上昇抑制剤
KR20240099961A (ko) 항염증 활성을 갖는 여주 초음파 추출물의 제조방법
KR20140004293A (ko) 문주란 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
KR20130127607A (ko) 아스테루빈의 신규 용도
JP2011057623A (ja) 骨粗鬆症予防または改善剤

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2018505974

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17766721

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 17766721

Country of ref document: EP

Kind code of ref document: A1